CSL Behring: Clinical Trials & Research Profile
Biopharma Industry (Global / Institutional) · Primary Focus: Rare Genetic, Women's Health, and Other
| Clinical Trial Metric | Verified Public Record |
|---|---|
| Organization Type | Consolidated Trial Sponsor |
| Institutional Sector & Location | Biopharma Industry (Global / Institutional) |
| Primary Therapeutic Area | Rare Genetic, Women's Health, and Other |
| Active Phase II & III Studies | 10 active (9 recruiting now) |
| Total Tracked Studies (2018 to 2026) | 32 (23 with California sites) |
| Completed vs Early-Stopped Studies | 14 completed / 8 stopped (25.0% stop rate) |
| Median Closed Enrollment | 81 participants |
| FDA Drugs@FDA Original Approvals | 1 all-time (1 from 2018 to 2026) |
| Physical Hospital Site Disclosure | 100.0% named hospital slots |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.
Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI -> · AI for Healthcare · Healthcare Price & Patent Cliff Crosswalk